Dr. Tyrone Malloy, medical director and CEO of the Atlanta Center for Women's Choice, helps perform research within the field of women s reproductive health. With his dedication to advancing the field, Dr. Tyrone Malloy served as one of the contributing research investigators involved with Panorama. Natera, a company dedicated to helping doctors provide families with their best chance or having a healthy child, strives to advance the technology that tests for fetal and genetic anomalies. Recently, the company developed Panorama, a noninvasive prenatal test that helps diagnose genetic conditions within the first trimester of pregnancy. Panorama serves as an alternative test to the invasive, risky procedures that are a common method for diagnosing genetic conditions during pregnancy. As a noninvasive prenatal test (NIPD), Natera’s Panorama uses a small amount of DNA from the fetus, which can be found within the mother's blood during pregnancy, to test for any anomalies. Once the blood sample is obtained from the mother, it is separated into three layers and analyzed with a sequencing machine. The machine's data is further analyzed in order to distinguish the fetal DNA from the mother's DNA, providing a fetal-only genome that can then be checked for anomalies. The Panorama prenatal test makes use of a new method known as NATUS. or next-generation aneuploidy testing using SNPs. This method is built based on SNP technology, women uses single nucleotide polymorphism to help detect variations between the fetal and maternal genomes. Through NATUS, the Panorama prenatal test is able to separate the fetal genome from maternal genome with a high level of accuracy, even when the fetal DNA differences are low. Due to this ability to detect separate genomes when DNA fraction is low, the Panorama prenatal test can be done as early as nine weeks after conception